Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy

Panelists discuss how to approach treatment decisions and management strategies for a 58-year-old woman with relapsed/refractory multiple myeloma who is post-autologous stem cell transplant, MRD-negative, and currently receiving bispecific antibody therapy, considering factors such as prior treatments, response duration, and long-term treatment goals.